BIIB Biogen Inc.

Biogen to Report Second Quarter 2017 Financial Results and Strategic Update on July 25, 2017

Biogen Inc. (NASDAQ:BIIB) today announced it will report second quarter 2017 financial results and a strategic update on Tuesday, July 25, 2017, before the financial markets open.

Following the release of the financials, the Company will host a live webcast with Biogen management from 8:00-9:30 am ET. To access the live webcast, please go to the investor relations section of Biogen’s website at www.biogen.com/investors. Following the live webcast, an archived version of the call will be available at the same URL.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

EN
20/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biogen Inc.

Biogen Inc.: Update to credit analysis

Our credit view of this issuer reflects its commercial and pipeline opportunities, weighed against declines in the legacy MS portfolio and event risk from debt-financed acquisitions.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Biogen Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 9 January 2026 in which we reassessed the appropriateness of the ratings in the context of the ...

 PRESS RELEASE

Biogen Receives European Commission Approval for High Dose Regimen of ...

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA1Biogen is dedicated to partnering with the SMA community to advance care through scientific innovation and a commitment to enhancing outcomes for people living with SMA CAMBRIDGE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BIIB) today announced the European Commission (EC...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch